Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
- PMID: 33288636
- PMCID: PMC8092553
- DOI: 10.1128/AAC.02489-20
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
Keywords: COVID-19; favipiravir.
Comment on
-
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).Antimicrob Agents Chemother. 2020 Nov 17;64(12):e02017-20. doi: 10.1128/AAC.02017-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32967849 Free PMC article.
References
-
- Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ, RECOVERY Collaborative Group. 2020. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 383:2030–2040. doi:10.1056/NEJMoa2022926. - DOI - PMC - PubMed
-
- Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. 28 October 2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. Clin Microbiol Infect doi:10.1016/j.cmi.2020.08.022. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
